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A B S T R A C T
H3N8 equine influenza virus (EIV) is an important and significant respiratory pathogen of horses. EIV is enzootic
in Europe and North America, mainly due to the suboptimal efficacy of current vaccines. We describe, for the
first time, the generation of a temperature sensitive (ts) H3N8 EIV live-attenuated influenza vaccine (LAIV) using
reverse-genetics approaches. Our EIV LAIV was attenuated (att) in vivo and able to induce, upon a single in-
tranasal administration, protection against H3N8 EIV wild-type (WT) challenge in both a mouse model and the
natural host, the horse. Notably, since our EIV LAIV was generated using reverse genetics, the vaccine can be
easily updated against drifting or emerging strains of EIV using the safety backbone of our EIV LAIV as master
donor virus (MDV). These results demonstrate the feasibility of implementing a novel EIV LAIV approach for the
prevention and control of currently circulating H3N8 EIVs in horse populations.
1. Introduction
Influenza A viruses (IAVs) are enveloped viruses in the
Orthomyxoviridae family that contain a segmented genome made of
eight single-stranded RNA molecules of negative polarity (Palese and
Shaw, 2007). IAVs are classified by subtypes based on the antigenicity
of the two major membrane glycoproteins: hemagglutinin (HA) and
neuraminidase (NA) (Palese and Shaw, 2007). Equine influenza, caused
by equine influenza virus (EIV), is the most common and important
respiratory infectious disease of horses. The H3N8 subtype of EIV was
first reported from infected horses in Florida in 1963 (Waddell et al.,
1963). At the end of the 1980s, H3N8 EIV diverged phylogenetically
and antigenically into the American and Eurasian lineages (Daly et al.,
1996). The American lineage evolved into Florida, Kentucky and South
American sublineages (Lai et al., 2001), and the Florida sublineage has
further diverged into the clades 1 and 2 that continue circulating
nowadays (Bryant et al., 2009; Murcia et al., 2011). Currently, viruses
from the sublineage Florida clade 1 are considered enzootic in the
United States (US) but have also produced outbreaks in other parts of
the world (Alves Beuttemmuller et al., 2016; Cowled et al., 2009;
Woodward et al., 2014; Yamanaka et al., 2008), while the clade 2
viruses of the Florida sublineage are predominant in Europe and Asia
(Fougerolle et al., 2017; Qi et al., 2010; Rash et al., 2017; Virmani et al.,
2010; Yondon et al., 2013). Based on international surveillance studies,
the World Organization for Animal Health (OIE, Office International
des Epizooties) recommends including representative viruses from both
the sublineage Florida clades 1 and 2 in the composition of H3N8 EIV
vaccines (OIE, 2017).
Vaccination is the most effective strategy, alongside isolation,
movement restriction and basic biosecurity measures, to prevent H3N8
EIV infections or to limit their consequences (Pica and Palese, 2013;
Wong and Webby, 2013). Despite the development and commerciali-
zation of vaccines for almost five decades, H3N8 EIV is still circulating
and considered endemic in numerous countries around the World, in-
cluding the US (Cullinane et al., 2010; Paillot, 2014; Paillot et al.,
2016). Different vaccine strategies have been available for decades for
the control of EIV in horses. These include, mainly, influenza in-
activated (IIV) and live-attenuated (LAIV) vaccines. Several vaccination
studies have showed that adjuvanted IIVs administered intramuscularly
induce humoral immunity, mostly by inducing neutralizing antibodies
against the viral HA protein, but are comparatively poor inducers of
cellular immunity (Belongia et al., 2009; Osterholm et al., 2012; Paillot,
2014). There is a wide panel of EIV IIVs, but the large majority of them
do not contain representative strains of both clades 1 and 2 of the
Florida sublineage of H3N8 EIV as recently recommended by the OIE.
LAIVs are administered intranasally, mimicking the natural route of
viral infection, and are able to induce both cellular and humoral im-
mune responses, providing better immunogenicity and protection than
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IIVs (Belshe et al., 2007; Gorse et al., 1991; Hoft et al., 2011; Paillot,
2014). The only currently available H3N8 EIV LAIV, Flu Avert I.N.
(Merck), was developed by passaging the A/equine/Kentucky/1/1991
H3N8 (Kentucky lineage) in embryonated chicken eggs at gradually
reduced temperatures to generate a temperature sensitive (ts) variant
that replicates efficiently at low temperatures (cold-adapted, ca)
(Wilson and Robinson, 2000; Youngner et al., 2001). It has been shown
that Flu Avert I.N. induced homologous (Lunn et al., 2001) and het-
erologous (Chambers et al., 2001) protection against H3N8 EIVs cir-
culating in the 1990s. Thus, if the circulating EIV matches the virus in
the vaccine (A/equine/Kentucky/1/1991), Flu Avert I.N. can confer
better protection against disease caused by EIVs than the IIV counter-
parts, inducing faster production of antibodies and broader immune
responses (Cullinane et al., 2010; Paillot, 2014; Paillot et al., 2016). For
this reason, LAIVs are ideal for their use to prevent and control EIV
infections (Cullinane et al., 2010; Paillot, 2014; Paillot et al., 2016).
However, although other LAIVs are updated yearly, Flu Avert I.N. has
not been updated or modified to match currently circulating EIV
strains. Therefore, and because of the ability of influenza virus to un-
dergo antigenic drift, there is not a good match of surface antigens
between contemporary EIV strains and the virus present in Flu Avert
I.N. The antigenic disparity between the virus in Flu Avert I.N. and
currently circulating EIV strains likely results in a significantly lower
vaccination impact (Cullinane et al., 2010; Paillot, 2014) and partial
protection (Park et al., 2009; Yates and Mumford, 2000). Moreover, Flu
Avert I.N. does not contain any representative Florida sublineage clade
1 and 2 H3N8 EIV strains, which is recommended by the OIE to be
included in H3N8 EIV vaccines (Paillot et al., 2016).
In order to develop an updated and more effective LAIV for the
treatment of currently circulating EIV strains, we used the same
strategy that we have recently implemented for the development of
LAIVs against H3N8 and H3N2 canine influenza viruses (CIVs) (Nogales
et al., 2016b; Rodriguez et al., 2017c). We introduced in the polymerase
basic 2 (PB2) and polymerase basic 1 (PB1) viral proteins of A/equine/
Ohio/1/2003 H3N8 (Florida sublineage clade 1) the mutations re-
sponsible for the ts, ca and att phenotype of A/Ann Arbor/6/60 H2N2
LAIV (Cox et al., 1988; Snyder et al., 1988), the master donor virus
(MDV) of the human LAIV (FluMist, MedImmune) and assessed its
safety and efficacy in both mice and horses. This is the first description
of a ts and att H3N8 EIV LAIV obtained by reverse-genetics technology.
2. Materials and methods
2.1. Cells and viruses
Human embryonic kidney 293 T cells (293 T; ATCC CRL-11268),
Madin-Darby canine kidney cells (MDCK; ATCC CCL-34) and equine
dermal cells (E. Derm NBL-6; ATCC CCL-57) were grown in Dulbecco's
modified Eagle's medium (DMEM; Mediatech, Inc.) supplemented with
10% fetal bovine serum (FBS), and 1% PSG (penicillin, 100 units/ml;
streptomycin 100 µg/ml; L-glutamine, 2 mM) at 37°C with 5% CO2
(Nogales et al., 2014b).
Recombinant wild-type (WT) and live attenuated (LAIV) H3N8 EIVs
were generated using A/equine/Ohio/1/2003 plasmid-based reverse
techniques (Martinez-Sobrido and Garcia-Sastre, 2010) and grown in
MDCK cells at 33°C. The commercially available A/equine/Kentucky/
1/1991 H3N8 LAIV (Flu Avert I.N., Merck) was also grown in MDCK
cells at 33°C. The A/equine/Kentucky/2014 H3N8, used in horse
challenge experiments, was grown in embryonated hen eggs. For in-
fections, virus preparations were diluted in phosphate buffered saline
(PBS) containing 0.3% bovine albumin (BA) and 1% penicillin and
streptomycin (PS) (PBS/BA/PS). After 1 h viral adsorption at room
temperature (RT), MDCK cells were maintained with post-infection
(p.i.) DMEM media supplemented with 0.3% BA, 1% PSG, and 1 μg/ml
of N-tosyl-L-phenylalanine chloromethyl ketone (TPCK)-treated trypsin
(Sigma). Viral titers were determined by immunofocus assay
(fluorescent forming units, FFU/ml) in MDCK cells at 33°C as previously
described (Nogales et al., 2014b) using the anti-NP monoclonal anti-
body (mAb) HB-65 (ATCC HB-65, HL16-L10-4R5).
2.2. Plasmids
For the generation of H3N8 EIV LAIV, the PB2 and PB1 genes of A/
equine/Ohio/1/2003 H3N8 were subcloned in a pUC19 plasmid (New
England BioLabs) to introduce the ts mutations PB2 N265S and PB1
K391E, E581G, and A661T by site-directed mutagenesis. The presence
of the introduced mutations was confirmed by sequencing. PB2- and
PB1-LAIV viral segments were subcloned from pUC19 into the ambi-
sense pDZ plasmid like the other A/equine/Ohio/1/2003 H3N8 viral
genes (PB2- and PB1-WT, PA, HA, NP, NA, M and NS) for virus rescue.
pDZ is an ambisense vector that contains a human RNA polymerase I
promoter and a mouse terminator sequence that encodes the negative
sense genomic RNA and, in opposite orientation to the polymerase I
unit, contains a polymerase II transcription cassette (chicken β-actin
promoter and polyA) that encode the viral proteins from the same viral
gene (Chambers et al., 2009).
2.3. Minigenome assay
To analyze the ability of A/equine/Ohio/1/2003 H3N8 WT and
LAIV polymerases to replicate and transcribe at different temperatures
(33°C, 37°C, and 39°C) E. Derm cells (12-well plate format, 5 × 105
cells/well, triplicates) were co-transfected in suspension, using
Lipofectamine 2000 (Invitrogen), with 0.25 μg of each of the A/equine/
Ohio/1/2003 H3N8 WT or LAIV ambisense pDZ-PB2 or PB2-LAIV, pDZ-
PB1 or PB1-LAIV, pDZ-PA and pDZ-NP plasmids, together with 0.5 μg of
a reporter minigenome (MG) viral (v)RNA-like expression plasmid en-
coding Gaussia luciferase (Gluc) driven by a murine RNA polymerase I
promoter (mpPol-I Gluc), and 0.1 μg of a mammalian expression
pCAGGS plasmid encoding Cypridina luciferase (Cluc) to normalize
transfection efficiencies (Cheng et al., 2015; Nogales et al., 2016b).
Cells transfected in the absence of the pDZ-NP plasmid were included as
negative control and empty pDZ plasmid was used to keep the amount
of transfected plasmid DNA constant in the negative control. At 48 h
post-transfection, Gluc and Cluc expression levels were determined
using the Biolux Gaussia and Cypridina Luciferase Assay kits (New
England BioLabs) and quantified with a Lumicount luminometer
(Packard). Reporter gene activation (Gluc) was normalized to that of
Cluc and is reported as fold induction over the level of induction for the
negative control (absence of NP). The mean values and standard de-
viations (SDs) were calculated and statistical analysis was performed
using a two-tailed Student t-test with Microsoft Excel software. Data are
represented as relative activity considering A/equine/Ohio/1/2003
H3N8 WT polymerase activity at each temperature as 100%.
2.4. Virus rescue
Viral rescue of A/equine/Ohio/1/2003 H3N8 WT and LAIV was
performed as previously described (Nogales et al., 2014b). Briefly, co-
cultures (1:1) of 293 T and MDCK cells (6-well plate format, 1 × 106
cells/well, triplicates) were co-transfected in suspension, using Lipo-
fectamine 2000, with 1 μg of the eight-ambisense A/equine/Ohio/1/
2003 H3N8 pDZ-PB2 or PB2-LAIV, -PB1 or PB1-LAIV, -PA, -HA, -NP,
-NA, -M, and -NS plasmids. At 12 h post-transfection, the medium was
replaced with p.i. DMEM medium supplemented with 0.5 μg/ml TPCK-
treated trypsin. Tissue culture supernatants (TCS) were collected at
three days post-transfection, clarified, and used to infect fresh mono-
layers of MDCK cells. Then, at three days p.i., recombinant viruses were
plaque purified and scaled up using MDCK cells at 33°C (Martinez-
Sobrido and Garcia-Sastre, 2010).
L. Rodriguez et al. Virology 516 (2018) 76–85
77
2.5. Virus growth kinetics
Multicycle viral growth kinetics was assessed by infecting MDCK
cells (12-well plate format, 5 × 105 cells/well, triplicates) with A/
equine/Ohio/1/2003 H3N8 WT and LAIV at a multiplicity of infection
(MOI) of 0.001. MDCK cells were also infected with Flu Avert I.N. using
an MOI of 0.001 as a control because it constitutes a ts H3N8 EIV. After
1 h viral adsorption at RT, infection medium was replaced by p.i.
DMEM medium supplemented with 0.5 μg/ml TPCK-treated trypsin and
plates were incubated at different temperatures (33°C, 37°C and 39°C).
TCS were collected at the indicated times p.i. and viral titers in TCS
were determined by immunofocus assay (FFU/ml) in MDCK cells as
indicated before (Nogales et al., 2014b). The mean values and SDs were
calculated using Microsoft Excel software.
2.6. Plaque assay
Confluent monolayers of MDCK cells (6-well plate format, 1 × 106
cells/well), were infected with the indicated viruses for 1 h at RT,
overlaid with agar, and incubated at 33°C, 37°C, or 39°C. At three days
p.i., the cells were fixed for 1 h at RT with 4% paraformaldehyde (PFA)
and the overlays were removed. Cells were then permeabilized (0.5%
Triton X-100 in PBS) for 15 min at RT and prepared for immunostaining
using the anti-NP mAb HB-65 and vector kits (Vectastain ABC vector
kits and DAB HRP substrate kit; Vector) according to the manufacturer's
specifications (Nogales et al., 2014a, 2014b, 2016a).
2.7. Mouse experiments
Six-to-eight-week-old female C57BL/6 mice were purchased from
the National Cancer Institute (NCI) and maintained in the animal care
facility at the University of Rochester under specific pathogen-free
conditions. All mouse protocols were approved by the University
Committee of Animal Resources and complied with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the
National Research Council (National Research Council (U.S.) et al.,
2011). To evaluate the in vivo attenuation of EIV LAIV, six mice were
anesthetized intraperitoneally (i.p.) with 2,2,2-tribromoethanol
(Avertin; 240 mg/kg of body weight) and then inoculated intranasally
(i.n.) with 30 μl of a virus preparation containing 105 FFU of EIV WT or
LAIV diluted in PBS (Rodriguez et al., 2017a). As a control, a group of
mice (N = 6) was also inoculated i.n. with 105 FFU of Flu Avert I.N.
Virus replication was determined by measuring viral titers in the lungs
and nasal mucosa of infected mice at days 2 (N = 3) and day 4 (N = 3)
p.i. To that end, mice from each group were euthanized by adminis-
tration of a lethal dose of Avertin and exsanguination, and the lungs and
nasal mucosa were recovered and homogenized (Rodriguez et al.,
2017a). Virus titers in both tissues were determined by immunofocus
assay (FFU/ml) as indicated before (Nogales et al., 2014b; Rodriguez
et al., 2017a).
For the vaccination and challenge experiments, 6–8-week-old fe-
male C57BL/6 mice (N = 6) were anesthetized and vaccinated i.n. with
PBS or 103 FFU of EIV WT, LAIV or Flu Avert I.N. (A/equine/Kentucky/
1/1991 H3N8 LAIV). At fourteen days post-vaccination, mouse sera
were collected by submandibular bleeding to evaluate the presence of
total antibodies by enzyme-linked immunosorbent assay (ELISA) and
neutralizing antibodies by hemagglutination inhibition (HAI) assay.
Twenty-four hours after mice bleeding, mice were challenged i.n. with
105 FFU of A/equine/Ohio/1/2003 H3N8 WT. After challenge, viral
replication in mouse lungs was evaluated at days 2 (N = 3) and 4 (N =
3) p.i. as described above (Rodriguez et al., 2017a).
2.8. Horse experiments
Male and female one-to-two-year-old horses of mixed breed (mainly
Standardbred-quarter horse crosses) were used. Horses were raised at
the University of Kentucky's Maine Chance Farm as part of a closed
herd, and had not been previously vaccinated for EIV. All horses were
seronegative for EIV H3N8, as measured by hemagglutination inhibi-
tion assay (HAI) prior to the start of the study (data not shown). Horse
experiments were approved by the University of Kentucky's
Institutional Animal Care and Use Committee (Protocol no. 2007-
0153). To evaluate the in vivo attenuation of A/equine/Ohio/1/2003
H3N8 LAIV, horses (N = 4) were inoculated by i.n. intubation with
2 ml of a virus preparation containing 4 × 108 FFU of A/equine/Ohio/
1/2003 H3N8 LAIV diluted in PBS. This dose, the maximum available
and similar to that used in the pilot studies of the Flu Avert I.N. LAIV by
Heska Corp. (Wilson and Robinson, 2000), was chosen so as to provide
the greatest likelihood of revealing any clinical signs induced by the
LAIV. Viral attenuation was tested daily by the observation of clinical
signs, measurement of rectal temperatures and by determining the
presence of virus in nasopharyngeal swabs that were taken prior to
vaccination (day 0) and daily for three days thereafter. The presence of
virus in nasal swabs was determined by quantitative (q)RT-PCR as de-
scribed before (Lu et al., 2009).
For the vaccination and challenge experiments, one-to-two years-
old horses (N = 4) were vaccinated by i.n. inoculation with 2 ml of a
virus preparation containing 4 × 108 FFU of A/equine/Ohio/1/2003
H3N8 LAIV. Another group of horses (N = 2) were used as a control
(unvaccinated). To avoid exposure of control horses to shed EIV LAIV,
the latter were pastured separately. At 27 days post-vaccination, all
horses (N = 6) were brought into a BSL-2 isolation barn. The challenge
virus, a heterologous Florida clade 1 EIV strain, A/equine/Kentucky/
2014 H3N8, was aerosolized using a DeVillbis Ultra-Neb 99 nebulizer,
and pumped into a tented stall (37.5 m3) to a density of 1 × 107 50%
egg infectious dose (EID50) units per m3, where it was inhaled by the
horses for 45 min (Mumford et al., 1990; Townsend et al., 2001). The
challenge dose of virus was similar to that we have used in previous
experimental infection of horses (Lunn et al., 2001). Horses were ob-
served daily thereafter and rectal temperatures, clinical signs, and na-
sopharyngeal swabs were taken prior to viral challenge (day 0) and
daily for seven days. qRT-PCR was performed on each nasopharyngeal
swab as described above, and non-quantitative virus detection was also
done on each swab by injection into embryonated eggs as described
before (Chambers et al., 2001). Infectious virus content of the naso-
pharyngeal swab samples from day 2 and day 3 post-challenge was
determined by EID50 titration.
3. ELISA
For the evaluation of the virus-specific antibodies levels present in
the sera of vaccinated mice, ELISAs were performed as previously de-
scribed (Nogales et al., 2016a, 2017, 2016b; Rodriguez et al., 2017a,
2017c). Briefly, 96-well plates were coated with cell lysates from mock-
or EIV-infected MDCK cells and incubated overnight (O/N) at 4°C.
Animal sera were assayed as two-fold dilutions (starting dilution of
1:100) and titers determined as described previously.
3.1. HAI assay
To evaluate the presence of EIV neutralizing antibodies, mouse sera
were treated with receptor-destroying enzyme (RDE; Denka Seiken) for
16 h at 37°C and heat inactivated for 30 min at 56°C. The sera were
then serially 2-fold diluted (starting dilution of 1:50) in 96-well V-
bottom plates and mixed 1:1 with 4 hemagglutinating units (HAU) of
A/equine/Ohio/1/2003 H3N8 during 30 min at RT. The HAI titers were
determined by adding 0.5% turkey red blood cells to the virus-antibody
mixtures for 30 min on ice (Nogales et al., 2016b). The geometric mean
titers and SDs from individual mice (N = 6) were calculated from the
last well where hemagglutination was inhibited. HAI for equine sera
was performed in essentially the same manner except that equine sera
were pre-treated with trypsin-periodate as described (Chambers and
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Reedy, 2014) to remove non-specific inhibitors of hemagglutination,
and chicken red blood cells were used.
4. Results
4.1. Generation and characterization of A/equine/Ohio/1/2003 H3N8
(EIV) LAIV
The commercially available EIV LAIV (Flu Avert I.N.) is made of an
EIV strain that circulated over 25 years ago (A/equine/Kentucky/1/
1991 H3N8) and has never been updated (Youngner et al., 2001). In
order to generate an updated EIV LAIV, we introduced four of the five
mutations responsible for the ts, ca and att phenotypes of the human A/
Ann Arbor/6/60 H2N2 LAIV (FluMist) (Cox et al., 1988; Snyder et al.,
1988) into the PB2 (N265S) and PB1 (K391E, E581G, A661T) genes of
A/equine/Ohio/1/2003 H3N8 (EIV) (Fig. 1A), a clade 1 Florida sub-
lineage strain recommended by the OIE to be included in the EIV
vaccine (Paillot et al., 2016). The A/equine/Ohio/1/2003 H3N8 NP
viral segment already contains a G in position 43. We then performed a
minigenome replication assay in E. Derm cells at different temperatures
(33°C, 37°C or 39°C) to analyze if the mutations introduced into the PB2
and PB1 genes of A/equine/Ohio/1/2003 H3N8 conferred a ts pheno-
type to the viral polymerase complex. At 33°C, both A/equine/Ohio/1/
2003 H3N8 WT and LAIV polymerases induced similar levels of Gluc
expression (Fig. 1B). However, Gluc expression was significantly re-
duced at 37°C and even more at 39°C (Fig. 1B).
Based on the ts phenotype observed in our minigenome assay
(Fig. 1), we next assessed if the introduced mutations in the viral PB2
and PB1 polymerase subunit of A/equine/Ohio/1/2003 H3N8 would
result in a virus with impaired growth kinetics at restrictive (37–39°C)
but not at permissive (33°C) temperatures. Thus, we rescued WT and
LAIV A/equine/Ohio/1/2003 H3N8 (referred to henceforth as EIV WT
and EIV LAIV, respectively) using previously described reverse-genetic
techniques (Martinez-Sobrido and Garcia-Sastre, 2010; Nogales et al.,
2014b). The viral replication kinetics of both viruses were determined
by evaluating viral titers in MDCK cells infected at low (0.001) multi-
plicity of infection (MOI) at different temperatures (33°C, 37°C or 39°C)
(Fig. 2A). Flu Avert I.N. was also included as a control. At 33°C, both
EIV WT and LAIV, and Flu Avert I.N., grew with similar kinetics and
reached peak titers at 48 h p.i. At 37°C and 39°C, EIV WT replication
was similar to that observed at 33°C. The titers of EIV LAIV and Flu
Avert I.N. were significantly reduced or not detected at 37°C and 39°C,
respectively, as compared to EIV WT (Fig. 2A). We also analyzed the
plaque phenotype of EIV WT and LAIV, and Flu Avert I.N. at the same
temperatures (33°C, 37°C or 39°C) (Fig. 2B). EIV WT plaque size was
similar at 33°C and 37°C, and slightly reduced at 39°C in accordance
with the minimal reduction in viral titers observed in the kinetics at
that temperature (Fig. 2A). In the case of EIV LAIV and Flu Avert I.N.,
the size of the plaques at 33°C was similar to that of EIV WT, but at high
temperatures, the plaque size was strongly reduced (37°C) or plaques
were not detected (39°C), corroborating the growth kinetic results
(Fig. 2A). Altogether, these results demonstrate that amino acid sub-
stitutions in the PB2 and PB1 polymerase subunits of A/equine/Ohio/
1/2003 H3N8 confer a ts phenotype similar to that observed in the
human A/Ann Arbor/6/60 H2N2 LAIV (Chan et al., 2008), These
characteristics have also been previously described for other influenza
A viruses (Cox et al., 2015; Jin et al., 2004; Nogales et al., 2016b;
Rodriguez et al., 2017c; Zhou et al., 2012).
4.2. Attenuation of EIV LAIV in mice
After elucidating that the growth kinetics (Fig. 2A) and the plaque
size (Fig. 2B) of EIV LAIV were affected at high temperatures (37°C and
39°C) but not at low temperatures (33°C), we next analyzed its ability to
replicate in vivo in a mouse model of influenza infection (Fig. 3). To that
end, mice (N = 3/time point) were infected i.n. with 105 FFU of EIV
WT or LAIV. Mice were also infected with 105 FFU of Flu Avert I.N. as
an internal control. Since no signs of infection were detected in mice
after infection with EIV WT, replication of EIV WT and LAIVs were
determined by evaluating viral titers from the lungs (Fig. 3A) and nasal
mucosa (Fig. 3B) at days 2 and 4 p.i. We decided to use this high dose
(105 FFU) to better evaluate the safety profile of the new EIV LAIV in
comparison with its WT counterpart. Notably, viral titers were only
detected in the lungs of mice infected with EIV WT at both times p.i.
(Fig. 3A), but no virus was detected in the lungs of mice infected with
EIV LAIV or Flu Avert I.N. (Fig. 3A). On the other hand, viral replication
was detected in the nasal mucosa of mice infected with the three viruses
(Fig. 3B), although the viral titers obtained in mice infected with EIV
LAIV and Flu Avert I.N. were significantly lower at both times p.i. as
compared to EIV WT. These results indicate that our EIV LAIV was also
attenuated in vivo at high temperatures (lungs) but able to replicate in
the nasal mucosa where the temperature is lower. Importantly, the
same in vivo ts phenotype was observed with Flu Avert I.N.
4.3. Mice immunized with EIV LAIV are protected against H3N8 EIV WT
challenge
To evaluate the immunity induced by EIV LAIV, groups of mice (N
= 6) were vaccinated i.n. with 103 FFU of WT and LAIV EIVs, mock
vaccinated with PBS or vaccinated i.n. with 103 FFU of Flu Avert I.N. as
negative and positive controls, respectively. We choose the 103 FFU/
mouse dose because base on the safety results (Fig. 3) is a secure dose
Fig. 1. Effect of temperature on the polymerase activity of A/equine/Ohio/1/2003
H3N8 (EIV) live-attenuated influenza vaccine (LAIV). A) Schematic representation
of segments 1 (PB2) and 2 (PB1) of WT (black) and LAIV (white) EIV (A/Equine/
Ohio/1/2003): Amino acid substitutions in the polymerase PB2 (N265S) and PB1
(K391E, E581G, and A661T) subunits of A/equine/Ohio/1/2003 H3N8 are indicated. B)
Minigenome activity: E. Derm cells (12-well plate format, 5 × 105 cells/well, tripli-
cates) were transiently co-transfected with 0.25 μg of ambisense pDZ expression plasmids
encoding the minimal requirements for viral genome replication and gene transcription
(PB2, PB1, PA and NP), together with 0.5 μg of a vRNA-like expression plasmid encoding
Gaussia luciferase (Gluc), and 0.1 μg of a pCAGGS Cypridinia luciferase (Cluc) plasmid to
normalize transfection efficiencies. Six hours after transfection, cells were placed at 33°C,
37°C or 39°C, and 48 h post-transfection, viral replication and transcription were eval-
uated by luminescence (Gluc). Gluc activity was normalized to that of Cluc. Data re-
present the means± SDs of the results determined for triplicate assays. Normalized re-
porter expression is relative to minigenome activity in the absence of the pDZ NP plasmid.
Data are represented as relative activity considering WT EIV polymerase activity at each
temperature as 100%. *, P< 0.005; **, P<0.001; NS not statistical using the Student T
test.
L. Rodriguez et al. Virology 516 (2018) 76–85
79
and, because in previous manuscripts in which we described the de-
velopment of LAIVs against H3N8 (Nogales et al., 2016b) and H3N2
(Rodriguez et al., 2017c) CIVs, this dose induced strong humoral and
cellular responses, as well as complete protection against challenge
with WT CIVs. Humoral immune responses were evaluated in mouse
sera collected 14 days post-vaccination. Antibody responses against
total EIV proteins were evaluated by ELISA using cell extracts from
virus-infected MDCK cells (Fig. 4A) (Nogales et al., 2016b; Rodriguez
et al., 2017c). Sera from mice vaccinated with EIV LAIV elicited high
serum IgG titers against EIV proteins, close to those obtained in the sera
from mice infected with EIV WT, while a significant lower titer of an-
tibodies was observed in the sera from mice immunized with Flu Avert
I.N. (Fig. 4A). Additionally, we performed HAI assays to evaluate the
presence of neutralizing antibodies in sera from vaccinated mice
(Fig. 4B). HAI titers against EIV were higher in the sera from mice
vaccinated with EIV LAIV than those observed in mice vaccinated with
Flu Avert I.N and were similar to those obtained in EIV WT infected
mice (Fig. 4B).
Next, we evaluated the protection efficacy induced by our EIV LAIV
against homologous A/equine/Ohio/1/2003 H3N8 WT challenge
(Fig. 5). Mice (N = 6) were vaccinated i.n. with 103 FFU of WT and
LAIV EIVs, Flu Avert I.N., or mock vaccinated with PBS. Fifteen days
after vaccination, mice were challenged with 105 FFU of A/equine/
Ohio/1/2003 H3N8 WT and viral titers in the lungs of infected mice (N
= 3 / group) were determined 2 and 4 days after challenge (Fig. 5).
Mock-vaccinated (PBS) mice exhibited lung viral titers of ~ 3 × 104
Fig. 2. In vitro characterization of EIV LAIV. A) Multicycle growth kinetics: MDCK cells (12-well plate format, 5 × 105 cells/well, triplicates) were infected (MOI, 0.001) with A/
equine/Ohio/1/2003 H3N8WT (black diamonds) and LAIV (white diamonds) and incubated at 33°C, 37°C and 39°C. As internal control, MDCK cells were also infected with Flu Avert I.N.
(grey triangles). Viral titers in TCS at the indicated times post-infection were determined by immunofocus assay (FFU/ml) using an anti-NP mAb (HB-65). Data represent the means +/-
SDs of the results determined in triplicate wells. Dotted black lines indicate the limit of detection (200 FFU/ml). P< 0.05: * WT vs. LAIV, ** WT vs. Flu Avert I.N. using the Student T test.
B) Plaque phenotype: MDCK cells (6-well plate format, 1 × 106 cells/well) were infected with A/equine/Ohio/1/2003 H3N8 WT and LAIV and overlaid with media containing agar.
MDCK cells infected with Flu Avert I.N. were included as internal control. Plates were incubated at 33°C, 37°C and 39°C and three days p.i., monolayers were immunostained with an anti-
NP mAb (HB-65).
Fig. 3. Attenuation of EIV LAIV in mice: Female 6-to-8-week-
old C57BL/6 mice (N = 6) were infected intranasally (i.n.) with 1
× 105 FFU of A/equine/Ohio/1/2003 H3N8 WT or LAIV. Mice
were also infected with 1 × 105 FFU with Flu Avert I.N. as in-
ternal control. Presence of viruses in lungs (A) and nasal mucosa
(B) of infected mice were evaluated at days 2 (N = 3) and 4 (N =
3) p.i. by immunofocus assay (FFU/ml) using an anti-NP mAb
(HB-65). Data represent the means± SDs. Dotted black lines in-
dicate the limit of detection (200 FFU/ml). ND, not detected. *,
P<0.05 using the Student T test.
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FFU/ml at days 2 and 4 post-challenge, whereas mice vaccinated with
WT or LAIV EIVs showed no detectable virus in the lungs at those times
(Fig. 5). Contrarily, A/equine/Ohio/1/2003 H3N8 WT was detected in
the lungs of mice vaccinated with Flu Avert I.N. at day 2 post-challenge
(~ 1 × 103 FFU/ml), but not at day 4 post-challenge (Fig. 5). These
results indicate that our EIV LAIV induced better protection than Flu
Avert I.N. against a challenge with A/equine/Ohio/1/2003 H3N8 WT
in mice, probably because of the antigenic match.
4.4. Attenuation of EIV LAIV in horses
We next evaluated the safety as well as the protection efficacy in-
duced by our EIV LAIV in horses, its natural host. To this end, four
horses were infected i.n. with 4 × 108 FFU of EIV LAIV and monitored
for clinical signs such as cough, nasal discharge, respiration and de-
pression, rectal temperature as well as viral shedding during the first 3
days after infection (Fig. 6). None of the horses showed significant
adverse effects. Three of the four horses showed a slight, bilateral
serous nasal discharge at days 2 and 3 p.i. and a single incidence of
coughing was observed (data not shown), however rectal temperatures
remained normal (37.5°C±0.2 on day of vaccination, 37.6°C± 0.4 on
Day + 3) (Fig. 6A). To measure the presence of EIV LAIV in naso-
pharyngeal swabs collected at days 0–3 p.i., a qRT-PCR was performed
on each swab (one swab for each nostril of each horse per day). Virus
shedding was detected in all nasopharyngeal swabs collected on days
1–3 p.i. showing a peak at day 2 p.i. (Fig. 6B), indicative of viral re-
plication. The horses were observed daily for an additional 25 days
although further swabbing past day 3 p.i. to ascertain the duration of
shedding was not done. During that period, one horse was euthanized
for an unrelated problem (equine protozoal myelitis). Similar safety
observations, including slight serous nasal discharge in 2/4 horses,
were obtained from the yearling horses that were subsequently chal-
lenged (Fig. 7). Following vaccination, all horses showed seroconver-
sion as their HAI antibody titers increased from undetected (< 10) to
20 (in three horses of both the safety and challenge trials) or 10 (in the
4th horse of both trials) and, as expected, no HAI antibodies were de-
tected in the sera from the unvaccinated control group. These results
demonstrate the safety profile of our EIV LAIV in horses and their
ability to replicate in the upper respiratory track, necessary for the
induction of immunity, including HA-specific antibody responses.
4.5. Horses immunized with EIV LAIV are protected against challenge with
heterologous EIV H3N8 WT
In order to evaluate the protection efficacy induced by our EIV LAIV
in its natural host, a group of horses (N = 4) was vaccinated as pre-
viously indicated with 4 × 108 FFU of EIV LAIV, or mock vaccinated (N
= 2), as negative control (Fig. 7). Twenty-seven days after vaccination,
horses were challenged by aerosolized with 1 × 107 EID50 units per m3
of A/equine/Kentucky/2014 H3N8 WT into a tented stall (37.5 m3) for
45 min. A/equine/Kentucky/14 (H3N8) virus, a Florida clade 1 strain is
heterologous yet antigenically similar to our EIV LAIV. During the first
10 days after challenge, horses were monitored for rectal temperatures
(Fig. 7A), presence of clinical symptoms of infection (cough, nasal
discharge, respiration, depression and swelling of lymph nodes) and
virus shedding (Fig. 7B). Both unvaccinated controls, but none of the
four horses vaccinated with EIV LAIV exhibited a characteristic spike of
pyrexia on day two post-challenge (Fig. 7A), and also one of the un-
vaccinated horses (number 2) was noted as lethargic on day two post-
challenge. Body temperatures of the two control horses returned to
normal or near-normal range on days three to six post-challenge, but
the unvaccinated horse number 2 had a second fever spike on day seven
post-challenge (Fig. 7A). Both unvaccinated horses had cough on days
three (horse number 2) and seven (horse number 1) different days post-
challenge, while coughing was not observed in any of the vaccinates.
Nasal discharge was observed in both control animals on day eight
(unvaccinated horse 1) or day two (unvaccinated horse 2) post-chal-
lenge. Notably, none of the vaccinated horses had cough or nasal dis-
charge. Another clinical symptom observed in the unvaccinated horses
was inspiratory wheeze on day six (unvaccinated horse 1) and day four
(unvaccinated horse 2) post-challenge, but not in the vaccinated horses.
Swelling of submandibular or parotid lymph nodes was observed in
three out of four vaccinates as well as both controls; however, the se-
verity and duration were greater in the controls. Late in the study (at
day 11 post-challenge) an independent veterinary assessment led to
both control horses, but none of the vaccines, being treated with anti-
biotics to promote full recovery. From a clinical standpoint, therefore,
Fig. 4. Induction of humoral responses by EIV LAIV in mice:
Female 6-to-8-week-old C57BL/6 mice (N = 6) were vaccinated
(i.n.) with 1 × 103 FFU of A/equine/Ohio/1/2003 H3N8 WT or
LAIV. Mice were also mock (PBS) vaccinated or vaccinated (i.n.)
with 1 × 103 FFU of Flu Avert I.N. as negative and positive
controls, respectively. At 14 days post-vaccination, mice were
bled and sera were collected and evaluated individually for the
presence of total antibodies by ELISA (A) and neutralizing anti-
bodies by HAI (B) against A/equine/Ohio/1/2003 H3N8. OD,
optical density. Data represent the means +/- SDs of the results
for 6 individual mice. ND, not detected. *, P< 0.05 wt vs. LAIV;
**, P< 0.005 wt vs. Flu Avert I.N. using the Student T test.
Fig. 5. Protection efficacy of EIV LAIV against EIV challenge in mice: Female 6- to-8-
week-old C57BL/6 mice (N = 6) were vaccinated with 1 × 103 FFU of A/equine/Ohio/1/
2003 H3N8 WT or LAIV. Mice were also mock (PBS) vaccinated or vaccinated (i.n.) with 1
× 103 FFU of Flu Avert I.N. as negative and positive controls, respectively. At 15 days
post-vaccination, mice were challenged with 1 × 105 FFU of A/equine/Ohio/1/2003
H3N8 WT and viral titers at days 2 (N = 3) and 4 (N = 4) post-challenge were evaluated
from lung homogenates by immunofocus assay (FFU/ml) using an anti-NP mAb (HB-65).
Dotted black line indicates the limit of detection (200 FFU/ml). Data represent the
means± SDs. ND, not detected.
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vaccinated horses appeared to be protected from challenge with wild-
type EIV.
A/equine/Kentucky/2014 H3N8 WT virus shedding in nasophar-
yngeal swabs was evaluated by inoculation of embryonated chicken
eggs and also by direct qRT-PCR (Fig. 7B). When the nasopharyngeal
swabs from vaccinated horses were inoculated in eggs, live virus was
detectable at least one time post-challenge, with an average of 2.25
days up to maximum of five days post-challenge. EID50 titrations of
infectious virus content in the swab material collected at day two or
three post-challenge showed titers between 1.7 × 102 and 3.16 × 103
EID50 units/ml. On the other side, both unvaccinated horses shed de-
tectable live virus for five and six days post-challenge, and viral titers in
the allantoic fluid at two days post-inoculation were 1.7 × 105 (number
2) and 4.6 × 107 (number 1) EID50 units/ml. Thus, our EIV LAIV did
not achieve sterilizing immunity against an heterologous challenge
after a single dose, but live virus shedding appeared to be reduced by at
least three orders of magnitude comparing with the unvaccinated
horses. These results were confirmed when we evaluated the presence
of virus by qRT-PCR in the daily nasopharyngeal swabs (Fig. 7B). In
both horses’ groups (vaccinated or unvaccinated) there was detectable
virus amplification continuously from day one post-challenge (or day
two for the vaccinated horse 2) through day seven when swabbing was
discontinued. The peaks shedding in unvaccinated horses were greater
than the values obtained in vaccinated horses with a difference between
5 and 15 cycles suggesting about 500 to 1500 times greater target
concentration than in vaccinated horses. By 14 days following viral
challenge, all horses exhibited 16–32-fold increases in serum HAI an-
tibody titers. Altogether, the results show that our EIV LAIV induced
protection against a heterologous challenge whit A/equine/Kentucky/
2014 H3N8 WT.
5. Discussion
Equine influenza, currently caused by H3N8 EIV, is the most
common and important respiratory infectious disease of horses (Daly
et al., 2011; Timoney, 2000). H3N8 EIV is highly contagious and has
the potential to spread rapidly through groups of naive horses in
aerosolized droplets that are dispersed by coughing (Daly et al., 2011;
Timoney, 2000). H3N8 EIV infections of horses have been responsible
for disrupting major equestrian events and causing significant economic
losses (Daly et al., 2011; Timoney, 2000). The equine population is
highly mobile, and horses travel long distances by road and/or air for
competitions and breeding purposes. When an infected horse is in-
troduced into a susceptible population, the spread of H3N8 EIV can be
explosive. Large outbreaks of H3N8 EIV are often associated with the
congregation of horses at equestrian events. Their dispersal after these
events can lead to further widespread dissemination of the virus. It is
currently estimated that H3N8 EIV outbreaks result in economic losses
of hundreds of millions of dollars. In endemic countries, the significant
economic losses caused by H3N8 EIV infections can be minimized by
vaccination of highly mobile horses. Indeed, many racing and eques-
trian authorities have mandatory vaccination policies that serve as in-
surance for business. On the other hand, non-endemic countries rely on
vaccination of imported horses and quarantine to prevent an incursion
of H3N8 EIV. The majority of these non-endemic countries also require
vaccination of their indigenous horse population to reduce the potential
impact of an H3N8 EIV incursion.
Traditional vaccination strategies support that vaccine strains must
represent viruses in circulation, and it is only through surveillance that
vaccine companies decide on which antigens should be used. Thus, EIV
surveillance and strain characterization are fundamental for H3N8 EIV
control programs based on vaccination. Importantly, vaccine manu-
facturers need to have a dynamic vaccination approach that allows the
rapid generation of novel vaccines to benefit the equine population
(Cullinane et al., 2010; Paillot, 2014; Paillot et al., 2016). Results from
cross-protection studies indicate that the majority of the inactivated
vaccines or the current commercially available LAIV Flu Avert I.N.
Fig. 6. Attenuation of EIV LAIV in horses: One-to-two years-old
horses of both sexes (N = 4) were inoculated i.n. with 4 × 108
FFU of A/equine/Ohio/1/2003 H3N8 LAIV. A) Graphic re-
presentation of the individual rectal temperatures measured in
each horse before (day 0) and during 3 days after vaccination. B)
The virus content in nasopharyngeal swabs were determined by
quantitative (q)RT-PCR and represented as quantification cycle
threshold (Ct). The swabs were taken before (day 0) and during 3
days post-vaccination for each horse nostril. Data represent the
means from each horse in each time post-vaccination± SDs.
Dotted black line indicates the limit of detection (Ct = 40).
Fig. 7. Protection efficacy of EIV LAIV against EIV challenge in horses: One-to-two
years-old horses of both sexes (N = 4) were vaccinated by i.n. intubation with 4 × 108
FFU of A/equine/Ohio/1/2003 H3N8 LAIV. Another group of horses (N = 2) were used
as a control (unvaccinated). At 27 days post-vaccination, horses were challenged by
aerosolized with 1 × 107 EID50 units per m3 into a tented stall (37.5 m3) for 45 min. A)
Rectal temperatures were measured daily by 10 days after challenge. B) Virus content in
nasopharyngeal swabs taken during 7 days post-challenge was analyzed by (q)RT-PCR
and represented as cycle threshold (Ct). Dotted black line indicates the limit of detection
(Ct = 40).
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would provide poor levels of protection if used in the face of an im-
minent outbreak because of the antigenic differences between the virus
in the vaccine and currently circulating H3N8 EIV strains (Paillot et al.,
2016). Notably, some recent H3N8 EIV outbreaks occurred in pre-
viously vaccinated animals, where the vaccine strain did not match the
circulating virus (Daly et al., 2003; Garner et al., 2011; Timoney, 2000).
The frequency of H3N8 EIV outbreaks, the continuous antigenic var-
iation (antigenic drift) of H3N8 EIV and examples of vaccine break-
down due to poorly antigenic match demonstrate the periodic need to
update EIV vaccines to prevent equine influenza in the equine popu-
lation. Moreover, EIV vaccines should include both clade 1 and clade 2
representative strains of the Florida sublineage, as recommended by the
OIE (Paillot et al., 2016).
Here, we report the development of a novel and more effective LAIV
for the prevention and control of equine influenza using reverse ge-
netics. This is the first time than an i.n. competitive ts LAIV based on
reverse genetic techniques has been developed for the prevention and
control of H3N8 EIV in horses. To generate our H3N8 EIV LAIV, we
introduced in the PB2 and PB1 viral genes from A/equine/Ohio/1/2003
H3N8, a strain recommended by the OIE to be part of EIV vaccines
(clade 1 of Florida sublineage) (OIE, 2017), the mutations responsible
for the ca, ts and att phenotypes of the human MDV A/Ann Arbor/6/60
H2N2 LAIV (Cox et al., 1988; Snyder et al., 1988) (Fig. 1). In vitro, the
recombinant A/equine/Ohio/1/2003 H3N8 LAIV (EIV LAIV) replicated
efficiently at low temperature (33°C), which is important for vaccine
production, but was restricted in replication at higher (37°C and 39°C)
temperatures, imperative for its safe implementation as LAIV (Fig. 2). In
a mouse model of influenza infection, our EIV LAIV was attenuated in
the lower respiratory tract (lungs) but not in the upper respiratory tract
(nasal mucosa) when compared to its WT counterpart (Fig. 3). Im-
portantly, the phenotype observed with our EIV LAIV in vivo and in vitro
was the same as that observed with the currently available H3N8 EIV
LAIV, Flu Avert I.N. Notably, our EIV LAIV was able to induce, upon a
single i.n. immunization dose, complete protection against challenge
with A/equine/Ohio/1/2003 H3N8 WT, contrary to Flu Avert I.N. that
only showed partial protection (Fig. 5). This partial protection observed
with Flu Avert I.N. is probably due to the fact that Flu Avert I.N. is
based on a virus that is antigenically distant from current EIV circu-
lating strains, including that used in our study (A/equine/Ohio/1/
2003). The analysis of humoral responses showed that the titer of total
(Fig. 4A), as well as neutralizing (Fig. 4B), antibodies against A/equine/
Ohio/1/2003 H3N8 WT was higher in sera from mice immunized with
our EIV LAIV than in sera from mice vaccinated with Flu Avert I.N. In
horses, its natural host, our EIV LAIV was safe since horses did not
develop any symptoms of infection including fever (Fig. 6A), and was
able to replicate in the upper respiratory track since the virus was de-
tected in nasal swabs (Fig. 6B), where the temperatures is low, which is
essential to induce mucosal immunity. Serum antibody titers in horses
following vaccination were low, which was also reported with the Flu
Avert I.N. LAIV in horses following a single dose (Lunn et al., 2001;
Townsend et al., 2001). Those authors argued that other indices of
immunological response, such as local mucosal immunity, appear to be
more relevant than serum antibody levels (Lunn et al., 2001; Townsend
et al., 2001). Importantly, in the horse vaccination and challenge ex-
periment with the heterologous A/equine/Kentucky/2014 H3N8 WT
virus (Florida clade 1 strain), none of the horses vaccinated with our
EIV LAIV showed clinical symptoms of infection after challenge, with
the exception of swelling of submandibular or parotid lymph nodes but
with a lower severity and duration than the observed in unvaccinated
horses. It is true than in all horses (vaccinated or unvaccinated) the
challenged A/equine/Kentucky/2014 H3N8 WT virus was detected in
nasopharyngeal swabs by qRT-PCR (Fig. 7B) and by growth in em-
bryonated chicken eggs, but in both systems the virus detected was
three orders of magnitude lower in vaccinated horses. All these results
indicate that our EIV LAIV induces protection against a A/equine/
Kentucky/2014 H3N8 WT heterologous challenge, even though it did
not induce sterilizing immunity. One possibility of this not complete
protection could be the need for a two-dose regime vaccination in naïve
horses. Another possibility could be a mismatch between both EIV
H3N8 viruses.
Compared to current H3N8 EIV IIVs, our H3N8 EIV LAIV approach
presents several advantages. First, our H3N8 EIV LAIV is administered
intranasally and mimics the natural route of viral infection, therefore
inducing mucosal immune responses at the site of infection (Kohlmeier
and Woodland, 2009; Murphy and Coelingh, 2002). Second, a sig-
nificant lower amount of virus in our H3N8 EIV LAIV is required to
induce superior protection than that required with H3N8 EIV IIVs
(Nogales et al., 2016b; Rodriguez et al., 2017c). Third, LAIVs have been
shown to stimulate more robust systemic humoral response (Cheng
et al., 2013; De Villiers et al., 2009; Katsura et al., 2012; Nogales et al.,
2016b; Rodriguez et al., 2017c; Victor et al., 2012) and elicit cellular
immunity (Cheng et al., 2013; Katsura et al., 2012), leading to re-
cruitment of influenza-specific CD8 T cells in the target tissues of the
respiratory tract (Baker et al., 2013; Guo et al., 2014; Katsura et al.,
2012; Nogales et al., 2016b; Powell et al., 2012; Rodriguez et al.,
2017c; Uraki et al., 2013). Fourth, a single immunization with our
H3N8 EIV LAIV would be sufficient to confer at least partial protection
against H3N8 EIV WT in a shorter period of time, compared with the
multiple doses required with the current inactivated vaccines. Finally,
our H3N8 EIV LAIV would provide better cross protection against an-
tigenically distinct H3N8 EIV strains than that provided by EIV IIVs,
diminishing the chance of EIV outbreaks. Some of the above advantages
are shared by the only commercially available H3N8 EIV LAIV, Flu
Avert I.N. (Chambers et al., 2001). However, our technology also offers
a number of additional advantages. First, the mutations introduced in
the PB2 and PB1 polymerase subunits of A/equine/Ohio/1/2003 H3N8
have been previously described to be responsible for the ts, ca and att
phenotype in the MDV of the human A/Ann Arbor/6/60 H2N2 LAIV
(FluMist) (Cox et al., 1988; Snyder et al., 1988) which have a proven
history of safety, immunogenicity and protection efficacy not only
against human viruses, but also against avian and equine influenza
viruses (Baz et al., 2015; Suguitan et al., 2006). Second, same ts and ca
mutations were also introduced in other influenza A viruses inducing
the same attenuated phenotype (Cox et al., 2015; Jin et al., 2004;
Nogales et al., 2016b; Rodriguez et al., 2017c; Zhou et al., 2012). Third,
the use of state-of-the-art reverse genetic techniques will facilitate, si-
milar to the case of the human LAIV, the fast and accurate development
of LAIV candidates for the control of currently circulating clades 1 and
2 strains of the Florida sublineage, or newly introduced EIV strains in
the case of a new outbreak in the horse population. To that end, our
temperature sensitive A/equine/Ohio/1/2003 H3N8 LAIV could be
used as a MDV to produce updated LAIV by the introduction of HA and
NA from antigenically different circulating H3N8 EIV strains or newly
introduced EIVs in the horse population, including EIVs with panzootic
potential. Finally, our approach could be updated to develop a bivalent
H3N8 EIV LAIVs that follow the current OIE recommendations to in-
clude representative strains of the clades 1 and 2 of Florida sublineages
of H3N8 EIVs. We have recently used a similar strategy to develop a
bivalent LAIV for the control of H3N8 and H3N2 canine influenza virus
infections (Rodriguez et al., 2017b). Based on the multiple advantages
over H3N8 EIV IIVs or the current LAIV, our novel platform represents
an easier and faster approach for the feasibility of implementing a safe
and more effective LAIV for the prevention and control of H3N8 EIVs in
the equine population, reducing the burden of current and future in-
fluenza disease in horses.
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